Long-term follow-up of people who received zamtocabtagene autoleucel for lymphoma
Follows adults who previously received zamtocabtagene autoleucel for relapsed lymphoma over time.
Plain-language title generated from the registry record
Registry title: Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Key facts
- Where
- Baltimore, Boston, Chicago, Dallas, Durham, Gilbert, Milwaukee, New Haven, Portland, Stanford, and Westwood, United StatesSee the 11 sites
Where in United States
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer CenterBaltimore, United StatesNot yet recruiting
- Dana-Farber Cancer InstituteBoston, United StatesTaking people
- Robert H Lurie Cancer CenterChicago, United StatesTaking people
- UT Southwestern Medical CenterDallas, United StatesTaking people
- Duke University Medical Center - Division of Hematologic MalignanciesDurham, United StatesTaking people
- Banner MD Anderson Cancer CenterGilbert, United StatesTaking people
- Froedtert Hospital and the Medical College of WisconsinMilwaukee, United StatesTaking people
- Yale UniversityNew Haven, United StatesTaking people
- Oregon Health and Science University Knight Cancer InstitutePortland, United StatesTaking people
- Stanford UniversityStanford, United StatesTaking people
- University of Kansas Cancer CenterWestwood, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Miltenyi Biomedicine GmbH
- Trial code
- NCT06116110
- Record updated
- 5 August 2026
- Original description
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.Read full original descriptionShow less
A Prospective, Observational, Long-term Follow-up Study for Subjects Who Previously Received Zamtocabtagene Autoleucel in a North American Miltenyi Biomedicine-Sponsored Clinical Study
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
Inclusion: Received zamtocabtagene autoleucel in a North American Miltenyi Biomedicine-sponsored clinical study and have not withdrawn consent to be followed or been deemed lost to follow-up; Provided written informed consent to participate in this study.
Exclusion: None.